The Public Health and Economic Effects of Various RSV Vaccination Strategies With RSVpreF Among Adults in France
Author(s)
Yasmine Fahfouhi, MSc1, MATHIAS VACHERET, PharmD2, Stephane Fievez, PhD1, Emmanuelle Blanc, PhD1, Maud beillat, PhD3, Romain Philippe Moreau, PharmD4, Rares Enache, PharmD5, Elise Cabout, MSc6, Elisabeth Botelho-Nevers, Md7, Paul Loubet, Md8, Reiko Sato, PhD9.
1Pfizer, Paris, France, 2PFIZER, Paris, France, 3PFIZER FRANCE, PARIS, France, 4stève consultants, Angers, France, 5stève consultants, Oullins-Pierre-Bénite, France, 6steve consultants, Oullins-Pierre-Bénite, France, 7CHU Saint-Etienne, Saint-Etienne, France, 8CHU Nîmes, Nimes, France, 9Pfizer Inc., Collegeville, PA, USA.
1Pfizer, Paris, France, 2PFIZER, Paris, France, 3PFIZER FRANCE, PARIS, France, 4stève consultants, Angers, France, 5stève consultants, Oullins-Pierre-Bénite, France, 6steve consultants, Oullins-Pierre-Bénite, France, 7CHU Saint-Etienne, Saint-Etienne, France, 8CHU Nîmes, Nimes, France, 9Pfizer Inc., Collegeville, PA, USA.
OBJECTIVES: Respiratory Syncytial Virus (RSV) is a significant cause of lower respiratory tract illness (LRTI) in adults, particularly the elderly and those with comorbidities. The bivalent stabilized prefusion F subunit vaccine (RSVpreF) was authorized by the EMA in 2023 and recommended in France in 2024. This study evaluates the potential impact of RSVpreF vaccination on hospitalization and healthcare costs in adults in France.
METHODS: A four-state Markov model (susceptible, RSV-hospitalization, outpatient consultations, death) compared 3 vaccination strategies to no vaccination over 5 years in individuals ≥75 and those 65-74 with cardiorespiratory comorbidities (n=8.2M) (current recommendation), individuals ≥75 and those 50-74 at risk (n=13.6M) (comorbidity-extended like US recommendations), and individuals ≥65 and those 50-64 at risk (n=17.8M) (age-extended, aligned with COVID19/influenza recommendations).
Vaccine efficacy against hospitalization was based on medically-attended LRTI with ≥3 symptoms from the RENOIR trial data and extrapolation. Vaccination coverage was assumed at 47.4% for individuals≥75 and 38.1% for those aged 60-74 with comorbidities. Hospitalization rates and costs were derived from French medical databases (RESVYR study) according to age and adjusted for comorbidities using German study estimating the excess risk of hospitalization for patients with comorbidities.
RESULTS: Without vaccination, 74,558 RSV-related hospitalizations were projected, totaling €347M in medical costs. The current recommendation could prevent 17,786 (-29%) hospitalizations and save €85M over 5 years. The comorbidity-extended recommendation could prevent 5,600 (+32%) additional hospitalizations from the current recommendation, reducing costs by a further €32M. Finally, the age-extended recommendation could prevent 3,635 (+15%) more hospitalizations than the comorbidity-extended recommendation, saving an additional €20M and resulting in 27,020 hospitalizations avoided over 5 years, with €137M in saved costs.
CONCLUSIONS: RSVpreF vaccination could prevent between 17,786-27,020 hospitalizations over 5 years and generates between €85M and €137M medical cost savings for the French health insurance, depending on the vaccination strategy.
METHODS: A four-state Markov model (susceptible, RSV-hospitalization, outpatient consultations, death) compared 3 vaccination strategies to no vaccination over 5 years in individuals ≥75 and those 65-74 with cardiorespiratory comorbidities (n=8.2M) (current recommendation), individuals ≥75 and those 50-74 at risk (n=13.6M) (comorbidity-extended like US recommendations), and individuals ≥65 and those 50-64 at risk (n=17.8M) (age-extended, aligned with COVID19/influenza recommendations).
Vaccine efficacy against hospitalization was based on medically-attended LRTI with ≥3 symptoms from the RENOIR trial data and extrapolation. Vaccination coverage was assumed at 47.4% for individuals≥75 and 38.1% for those aged 60-74 with comorbidities. Hospitalization rates and costs were derived from French medical databases (RESVYR study) according to age and adjusted for comorbidities using German study estimating the excess risk of hospitalization for patients with comorbidities.
RESULTS: Without vaccination, 74,558 RSV-related hospitalizations were projected, totaling €347M in medical costs. The current recommendation could prevent 17,786 (-29%) hospitalizations and save €85M over 5 years. The comorbidity-extended recommendation could prevent 5,600 (+32%) additional hospitalizations from the current recommendation, reducing costs by a further €32M. Finally, the age-extended recommendation could prevent 3,635 (+15%) more hospitalizations than the comorbidity-extended recommendation, saving an additional €20M and resulting in 27,020 hospitalizations avoided over 5 years, with €137M in saved costs.
CONCLUSIONS: RSVpreF vaccination could prevent between 17,786-27,020 hospitalizations over 5 years and generates between €85M and €137M medical cost savings for the French health insurance, depending on the vaccination strategy.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE720
Topic
Economic Evaluation, Health Technology Assessment
Topic Subcategory
Budget Impact Analysis
Disease
Vaccines